Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shot up 12.9% during trading on Wednesday . The stock traded as high as C$1.76 and last traded at C$1.75. 62,156 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 122,649 shares. The stock had previously closed at C$1.55.
Medicenna Therapeutics Stock Up 21.3 %
The business’s 50 day simple moving average is C$1.45 and its 200 day simple moving average is C$0.79. The company has a current ratio of 5.00, a quick ratio of 4.65 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of C$130.92 million, a PE ratio of -6.74 and a beta of 1.16.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Featured Stories
- Five stocks we like better than Medicenna Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 Warren Buffett Stocks to Buy Now
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How to invest in marijuana stocks in 7 steps
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
